Viridian Therapeutics, Inc. to Post FY2028 Earnings of $3.76 Per Share, B. Riley Forecasts (NASDAQ:VRDN)

Viridian Therapeutics, Inc. (NASDAQ:VRDNFree Report) – B. Riley issued their FY2028 earnings estimates for shares of Viridian Therapeutics in a report released on Thursday, March 21st. B. Riley analyst K. Patel expects that the company will post earnings per share of $3.76 for the year. B. Riley has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.25) per share.

Viridian Therapeutics (NASDAQ:VRDNGet Free Report) last issued its earnings results on Tuesday, February 27th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.37). The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.15 million. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. The company’s quarterly revenue was down 31.4% on a year-over-year basis. During the same period last year, the business earned ($1.13) EPS.

A number of other research firms also recently weighed in on VRDN. Needham & Company LLC restated a “buy” rating and set a $30.00 price target on shares of Viridian Therapeutics in a report on Wednesday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Viridian Therapeutics in a report on Thursday, February 29th. Wedbush lifted their target price on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Oppenheimer lifted their target price on shares of Viridian Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a report on Tuesday, December 19th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $35.00 price objective on shares of Viridian Therapeutics in a report on Thursday, December 14th. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $36.60.

Read Our Latest Stock Report on VRDN

Viridian Therapeutics Stock Down 4.1 %

Viridian Therapeutics stock opened at $18.01 on Monday. The company has a market capitalization of $1.13 billion, a P/E ratio of -3.39 and a beta of 1.08. The firm’s fifty day simple moving average is $19.02 and its 200-day simple moving average is $17.54. The company has a current ratio of 18.26, a quick ratio of 18.26 and a debt-to-equity ratio of 0.09. Viridian Therapeutics has a 1-year low of $10.93 and a 1-year high of $30.30.

Hedge Funds Weigh In On Viridian Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VRDN. Braidwell LP acquired a new position in Viridian Therapeutics in the second quarter valued at about $28,698,000. Polar Capital Holdings Plc lifted its position in shares of Viridian Therapeutics by 190.9% during the second quarter. Polar Capital Holdings Plc now owns 1,600,000 shares of the company’s stock worth $38,064,000 after purchasing an additional 1,050,000 shares in the last quarter. Vestal Point Capital LP acquired a new position in shares of Viridian Therapeutics during the fourth quarter worth approximately $21,780,000. Alliancebernstein L.P. acquired a new position in shares of Viridian Therapeutics during the fourth quarter worth approximately $26,985,000. Finally, State Street Corp lifted its position in shares of Viridian Therapeutics by 159.0% during the third quarter. State Street Corp now owns 1,178,549 shares of the company’s stock worth $24,172,000 after purchasing an additional 723,484 shares in the last quarter.

Insider Activity

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 476,190 shares of the firm’s stock in a transaction dated Monday, January 22nd. The shares were acquired at an average cost of $21.00 per share, for a total transaction of $9,999,990.00. Following the transaction, the director now owns 1,839,954 shares in the company, valued at $38,639,034. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.43% of the stock is owned by company insiders.

About Viridian Therapeutics

(Get Free Report)

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

Further Reading

Earnings History and Estimates for Viridian Therapeutics (NASDAQ:VRDN)

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.